Repligen (RGEN) Bank of America Global Healthcare Conference 2026 summary

Financial performance and outlook

• Achieved a strong first quarter, exceeding expectations in both revenue and earnings, leading to increased confidence in full-year guidance and a raised EPS outlook.

• Organic growth for Q1 was 11%, with similar expectations for Q2, supporting the annual growth target without requiring acceleration in the second half.

• Margin expansion initiatives are underway, including the launch of a Transformation Office to drive sustainable and accelerated improvements, targeting about one point of margin expansion by the end of 2027.

• Announced the sale of a small, unprofitable segment and signed an OEM partnership in China to enhance local competitiveness.

Segment and product performance

• Protein and chromatography segments experienced strong growth, with analytics also showing significant traction, particularly from new product launches.

• Filtration grew at a mid-single-digit rate, with some headwinds in ATF due to customer inventory management, expected to rebound next year.

• Equipment growth was driven by analytics (notably the SoloVPE PLUS upgrade cycle) and mixers, while traditional downstream filtration systems remained flat due to delayed customer decisions.

Market and customer dynamics

• Growth is primarily driven by monoclonal antibodies (mAbs), while new modalities, especially gene therapy, are currently dilutive due to a specific customer headwind, but cell therapy shows encouraging momentum.

• Emerging biotech funding has improved, with four consecutive quarters of growth, but order conversion lags as spending cycles remain extended.

• China is rebounding, with new leadership and an OEM partnership supporting local manufacturing and future expansion opportunities.